Fallopian Tube

Treatment Stage Protocol Title ClinicalTrials.Gov Link Penn Research Coordinator Am I Eligible? 
Recurrent GOG 3104: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy NCT06486441 Shavon Rochester Eligibility Criteria
Recurrent GOG 3096: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug
Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025 Kristina Powell Eligibility Criteria
Recurrent ATRN: A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors NCT04905914 Andrea Standish, RN Eligibility Criteria
Recurrent GOG 3066: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04814108 Kristina Powell

Eligibility Criteria 

Recurrent STAR-101: A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma NCT05568680 Andrea Standish, RN Eligibility Criteria
Recurrent NP-G2-044-P2-01: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies NCT05023486 Shavon Rochester

Eligibility Criteria

Recurrent NRG-GY031: A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer NCT05950464 Christine Pae

ON HOLD

Eligibility Criteria

Recurrent Phase 1/2 Study of REGN5668 (MUC16 X CD28, A Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3) NCT04590326 Katie Hayes, RN Eligibility Criteria
Maintenance UPROAR: A phase II evaluation of maintenance therapy combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer NCT05887609 Kristina Powell Eligibility Criteria